Acadia Pharmaceuticals | ACAD - Los Gastos De Explotación





Los Gastos De Explotación Cambio Fecha
Acadia Pharmaceuticals USD 270.12M 2.55M 2026-06
ALKERMES USD 1.81B 57.02M 2026-06
Alnylam Pharmaceuticals USD 1.06B 160.97M 2026-06
Biogen USD 2.98B 1.02B 2026-06
BioMarin Pharmaceutical USD 6.32B 5.69B 2026-06
Bristol-Myers Squibb USD 22.32B 2.25B 2026-06
Cara Therapeutics USD 7.05M 1.11M 2026-03
Corcept Therapeutics USD 214.85M 343K 2026-06
Cytokinetics USD 207.8M 7.22M 2026-06
Eisai JPY 209.6B 6.14B 2026-06
Eli Lilly USD 10.52B 496M 2026-06
Incyte USD 973.64M 4.65B 2026-06
J&J USD 17.83B 388M 2026-06
Moderna USD 960M 817M 2026-06
Neurocrine Biosciences USD 739.1M 139.2M 2026-06
Pfizer USD 85.19B 4.91B 2026-06
Prothena USD 25.29M 1.94M 2026-03
PTC Therapeutics USD 226.66M 19.64M 2026-03
Sarepta Therapeutics USD 387.96M 15.59M 2026-06
Ultragenyx Pharmaceutical USD 289M 16M 2026-06
Vanda Pharmaceuticals USD -1.14B 1.6B 2025-12
Vertex Pharmaceuticals USD 2.07B 217.1M 2026-06